Published in J Clin Aesthet Dermatol on November 01, 2013
Brain-skin connection: stress, inflammation and skin aging. Inflamm Allergy Drug Targets (2014) 0.95
Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? J Invest Dermatol (1991) 2.52
Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol (2009) 2.43
Filaggrin in atopic dermatitis. J Allergy Clin Immunol (2008) 1.89
pH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity/cohesion. J Invest Dermatol (2003) 1.75
Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum. J Invest Dermatol (2008) 1.67
Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol (1998) 1.56
Sustained serine proteases activity by prolonged increase in pH leads to degradation of lipid processing enzymes and profound alterations of barrier function and stratum corneum integrity. J Invest Dermatol (2005) 1.51
Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr Opin Allergy Clin Immunol (2009) 1.43
Stratum corneum lipid abnormalities in atopic dermatitis. Arch Dermatol Res (1991) 1.37
Sphingolipid activator proteins are required for epidermal permeability barrier formation. J Biol Chem (1999) 1.32
The stratum corneum: structure and function in health and disease. Dermatol Ther (2004) 1.21
Roles for tumor necrosis factor receptor p55 and sphingomyelinase in repairing the cutaneous permeability barrier. J Clin Invest (1999) 1.21
High-expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis. J Invest Dermatol (2000) 1.09
Analysis of beta-glucocerebrosidase and ceramidase activities in atopic and aged dry skin. Acta Derm Venereol (1994) 1.04
Permeability barrier requirements regulate epidermal beta-glucocerebrosidase. J Lipid Res (1994) 1.04
Abnormal expression of sphingomyelin acylase in atopic dermatitis: an etiologic factor for ceramide deficiency? J Invest Dermatol (1996) 1.03
Role of ceramides in barrier function of healthy and diseased skin. Am J Clin Dermatol (2005) 0.99
Decreased level of prosaposin in atopic skin. J Invest Dermatol (1997) 0.86
The skin of atopic dermatitis patients contains a novel enzyme, glucosylceramide sphingomyelin deacylase, which cleaves the N-acyl linkage of sphingomyelin and glucosylceramide. Biochem J (2000) 0.82
Repair and maintenance of the epidermal barrier in patients diagnosed with atopic dermatitis: an evaluation of the components of a body wash-moisturizer skin care regimen directed at management of atopic skin. J Clin Aesthet Dermatol (2011) 0.78
A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med (2015) 4.05
Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol (2005) 1.77
Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc Natl Acad Sci U S A (2002) 1.56
Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. J Am Acad Dermatol (2008) 1.44
Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol (2006) 1.43
The clinical relevance of maintaining the functional integrity of the stratum corneum in both healthy and disease-affected skin. J Clin Aesthet Dermatol (2011) 1.40
General anesthesia for pediatric dermatologic procedures: risks and complications. Arch Dermatol (2005) 1.39
Infantile hemangiomas: an update on pathogenesis and therapy. Pediatrics (2012) 1.24
Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis (2010) 1.22
Venous malformations in blue rubber bleb nevus syndrome: variable onset of presentation. J Am Acad Dermatol (2004) 1.22
Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol (2005) 1.20
Dermatofibrosarcoma protuberans: a case report and review of the literature. J Clin Aesthet Dermatol (2008) 1.16
Myeloid cells in infantile hemangioma. Am J Pathol (2006) 1.16
Atypical mycobacterial cutaneous infections. Dermatol Clin (2009) 1.15
Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol (2013) 1.08
Use of oral isotretinoin in the management of rosacea. J Clin Aesthet Dermatol (2011) 1.07
Early stroke and cerebral vasculopathy in children with facial hemangiomas and PHACE association. Pediatrics (2006) 1.05
Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: focus on antibiotic resistance. Cutis (2007) 1.03
A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis. J Am Acad Dermatol (2005) 1.01
Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics (2013) 1.00
Anti-TNF agents for the treatment of psoriasis. J Drugs Dermatol (2009) 0.98
Anti-inflammatory activity of tetracyclines. Dermatol Clin (2007) 0.98
Pathways to managing atopic dermatitis: consensus from the experts. J Clin Aesthet Dermatol (2013) 0.98
Calciphylaxis: a review. J Clin Aesthet Dermatol (2008) 0.98
Identifying potential regulators of infantile hemangioma progression through large-scale expression analysis: a possible role for the immune system and indoleamine 2,3 dioxygenase (IDO) during involution. Lymphat Res Biol (2003) 0.94
New treatments for tinea capitis. Curr Opin Infect Dis (2004) 0.94
A prospective study of cutaneous findings in newborns in the United States: correlation with race, ethnicity, and gestational status using updated classification and nomenclature. J Pediatr (2012) 0.93
Demodex dermatitis: a retrospective analysis of clinical diagnosis and successful treatment with topical crotamiton. J Clin Aesthet Dermatol (2009) 0.92
Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol (2010) 0.92
Pathogenesis of acne vulgaris: recent advances. J Drugs Dermatol (2009) 0.92
Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris: Practical Considerations for the Clinician Based on Current Data and Clinical Experience. J Clin Aesthet Dermatol (2012) 0.92
Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: a status report. Dermatol Clin (2009) 0.91
Children with atopic dermatitis appear less likely to be infected with community acquired methicillin-resistant Staphylococcus aureus: the San Diego experience. Pediatr Dermatol (2010) 0.90
Acne Vulgaris and the Epidermal Barrier: Is Acne Vulgaris Associated with Inherent Epidermal Abnormalities that Cause Impairment of Barrier Functions? Do Any Topical Acne Therapies Alter the Structural and/or Functional Integrity of the Epidermal Barrier? J Clin Aesthet Dermatol (2013) 0.90
A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. J Drugs Dermatol (2009) 0.89
Psychosocial judgements and perceptions of adolescents with acne vulgaris: A blinded, controlled comparison of adult and peer evaluations. Biopsychosoc Med (2011) 0.87
Skin cancer in asians: part 2: melanoma. J Clin Aesthet Dermatol (2009) 0.87
Pathogenesis of acne vulgaris: what's new, what's interesting and what may be clinically relevant. J Drugs Dermatol (2011) 0.86
Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol (2008) 0.85
Acute generalized exanthematous pustulosis: an enigmatic drug-induced reaction. Cutis (2009) 0.85
The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. Cutis (2007) 0.85
Tinea capitis: a treatment update. Pediatr Ann (2005) 0.85
Evaluating Clinical Use of a Ceramide-dominant, Physiologic Lipid-based Topical Emulsion for Atopic Dermatitis. J Clin Aesthet Dermatol (2011) 0.85
Solitary sclerotic fibroma. J Clin Aesthet Dermatol (2009) 0.84
Benzoyl peroxide microsphere cream as monotherapy and combination treatment of acne. J Drugs Dermatol (2008) 0.84
Atopic dermatitis and the stratum corneum: part 1: the role of filaggrin in the stratum corneum barrier and atopic skin. J Clin Aesthet Dermatol (2013) 0.84
Healthcare utilization and costs of patients with rosacea in an insured population. J Drugs Dermatol (2008) 0.83
Comprehensive medical management of rosacea: an interim study report and literature review. J Clin Aesthet Dermatol (2008) 0.83
Epstein-Barr virus-associated genital ulcers: an under-recognized disorder. Pediatr Dermatol (2007) 0.83
Skin cancer in asians: part 1: nonmelanoma skin cancer. J Clin Aesthet Dermatol (2009) 0.81
Tretinoin photostability: comparison of micronized tretinoin (0.05%) gel and tretinoin (0.025%) gel following exposure to ultraviolet a light. J Clin Aesthet Dermatol (2012) 0.80
Combining clindamycin 1%-benzoyl peroxide 5% gel with multiple therapeutic options. Cutis (2006) 0.80
Absence of Degradation of Tretinoin When Benzoyl Peroxide is Combined with an Optimized Formulation of Tretinoin Gel (0.05%). J Clin Aesthet Dermatol (2010) 0.80
Safety and Efficacy of Multiple 16-week Courses of Topical Imiquimod for the Treatment of Large Areas of Skin Involved with Actinic Keratoses. J Clin Aesthet Dermatol (2009) 0.79
Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria. J Clin Aesthet Dermatol (2013) 0.79
A 3-step acne system containing solubilized benzoyl peroxide versus clindamycin-benzoyl peroxide. Cutis (2009) 0.79
Tinea capitis in infants: recognition, evaluation, and management suggestions. J Clin Aesthet Dermatol (2012) 0.79
Pediatric "STUMP" lesions: evaluation and management of difficult atypical Spitzoid lesions in children. J Am Acad Dermatol (2011) 0.79
Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectives. J Clin Aesthet Dermatol (2011) 0.79
Tinea capitis in the United States: Diagnosis, treatment, and costs. J Am Acad Dermatol (2006) 0.79
Acne life cycle: the spectrum of pediatric disease. Semin Cutan Med Surg (2011) 0.79
Systemic retinoid therapy: a status report on optimal use and safety of long-term therapy. Dermatol Clin (2007) 0.78
Repair and maintenance of the epidermal barrier in patients diagnosed with atopic dermatitis: an evaluation of the components of a body wash-moisturizer skin care regimen directed at management of atopic skin. J Clin Aesthet Dermatol (2011) 0.78
Nonsteroidal treatment of atopic dermatitis in pediatric patients with a ceramide-dominant topical emulsion formulated with an optimized ratio of physiological lipids. J Clin Aesthet Dermatol (2011) 0.78
Oral trimethoprim/sulfamethoxazole in the treatment of acne vulgaris. Cutis (2007) 0.78
Over 25 Years of Clinical Experience With Ivermectin: An Overview of Safety for an Increasing Number of Indications. J Drugs Dermatol (2016) 0.77
Clinical study results of desoximetasone spray, 0.25% in moderate to severe plaque psoriasis. J Drugs Dermatol (2013) 0.77
Overcoming the Barrier Treatment of Ichthyosis: A Combination-therapy Approach. J Clin Aesthet Dermatol (2010) 0.77
Evolving perspectives on the etiology and pathogenesis of acne vulgaris. J Drugs Dermatol (2015) 0.77
Onychomycosis: epidemiology, diagnosis, and treatment in a changing landscape. J Drugs Dermatol (2015) 0.77
The sequence of inflammation, relevant biomarkers, and the pathogenesis of acne vulgaris: what does recent research show and what does it mean to the clinician? J Drugs Dermatol (2013) 0.76
Atopic dermatitis and the stratum corneum: part 3: the immune system in atopic dermatitis. J Clin Aesthet Dermatol (2013) 0.76
Optimal management of papulopustular rosacea: rationale for combination therapy. J Drugs Dermatol (2012) 0.76
Transitioning from brand to generic with topical products and the importance of maintaining the formulation and therapeutic profiles of the original product: focus on clocortolone pivalate 0.1% cream. J Drugs Dermatol (2014) 0.76
A status report on drug-associated acne and acneiform eruptions. J Drugs Dermatol (2010) 0.75
Coal tar 2% foam in combination with a superpotent corticosteroid foam for plaque psoriasis: case report and clinical implications. J Clin Aesthet Dermatol (2010) 0.75
Mycetoma clinically masquerading as squamous cell carcinoma: case report and literature review. J Clin Aesthet Dermatol (2009) 0.75
Primary carcinosarcoma of the ear: case report and review of the literature. J Clin Aesthet Dermatol (2009) 0.75
Avoiding the legal "blemish": medicolegal pitfalls in dermatology. J Clin Aesthet Dermatol (2009) 0.75
Daily application of fluocinonide 0.1% cream for the treatment of atopic dermatitis. J Clin Aesthet Dermatol (2009) 0.75
Erythropoietic protoporphyria: a case report and literature review. J Clin Aesthet Dermatol (2010) 0.75
A Comprehensive Review of Clocortolone Pivalate 0.1% Cream: Structural Development, Formulation Characteristics, and Studies Supporting Treatment of Corticosteroid-responsive Dermatoses. J Clin Aesthet Dermatol (2012) 0.75
Efficacy and Tolerability of a Three-Step Acne System Containing a Solubilized Benzoyl Peroxide Lotion versus a Benzoyl Peroxide/Clindamycin Combination Product: An Investigator-Blind, Randomized, Parallel-Group Study. J Clin Aesthet Dermatol (2008) 0.75
The changing face of challenges in the management of acne and rosacea. J Drugs Dermatol (2014) 0.75
The Efficacy and Safety of Azelaic Acid 15% Foam in the Treatment of Truncal Acne Vulgaris. J Drugs Dermatol (2017) 0.75
What more can we learn about acne and rosacea? Just keep reading, questioning, and searching for clinical relevance beyond the limitations of clinical trials. J Drugs Dermatol (2013) 0.75
The effect of benzoyl peroxide 9.8% emollient foam on reduction of Propionibacterium acnes on the back using a short contact therapy approach. J Drugs Dermatol (2012) 0.75
Acne through the ages: case-based observations through childhood and adolescence. Clin Pediatr (Phila) (2008) 0.75
Pediatric Onychomycosis: The Emerging Role of Topical Therapy. J Drugs Dermatol (2016) 0.75
Message from the guest editor. J Drugs Dermatol (2012) 0.75
Persistent subcutaneous nodule: "sealed with a kiss". Pediatr Infect Dis J (2011) 0.75
Optimizing topical antifungal therapy for superficial cutaneous fungal infections: focus on topical naftifine for cutaneous dermatophytosis. J Drugs Dermatol (2013) 0.75
Topical fluticasone propionate lotion does not cause HPA axis suppression. J Pediatr (2006) 0.75
Pityriasis lichenoides and idiopathic thrombocytopenic purpura in a young girl. Pediatr Dermatol (2006) 0.75
Pustules on the nose of an 11-year-old girl. Pediatr Dermatol (2007) 0.75
The treatment of inflammatory facial dermatoses with topical corticosteroids: focus on clocortolone pivalate 0.1% cream. J Drugs Dermatol (2012) 0.75
Topical tazarotene in acne vulgaris: treatment approaches. Cutis (2004) 0.75
Topical retinoids in the management of acne: the best path to clear results. Cutis (2004) 0.75